Survey of aspirin administration in systemic mastocytosis

Prostaglandins and Other Lipid Mediators

Volumn 88, Issue 3-4, 2009, Pages 122-124

  Butterfield, Joseph H ^a  

^a MAYO CLINIC   (United States)

Author keywords

Aspirin; Prostaglandin D2; Systemic mastocytosis

Indexed keywords

11 EPIPROSTAGLANDIN F2 ALPHA; ACETYLSALICYLIC ACID; N METHYLHISTAMINE; PROSTAGLANDIN D2;

ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOATING; CLINICAL LABORATORY; DIARRHEA; DIZZINESS; FLUSHING; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LABORATORY TEST; MEDICAL RECORD REVIEW; PATIENT ASSESSMENT; PROSTAGLANDIN BLOOD LEVEL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN URINE LEVEL; RETROSPECTIVE STUDY; SIDE EFFECT; SOLID PHASE EXTRACTION; SYSTEMIC MASTOCYTOSIS; TANDEM MASS SPECTROMETRY; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ASPIRIN; DINOPROST; DRUG ADMINISTRATION SCHEDULE; HUMANS; MASTOCYTOSIS, SYSTEMIC; PLATELET AGGREGATION INHIBITORS; PROSTAGLANDIN D2;

EID: 62849113861     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2009.01.001     Document Type: Article

References (35)

1. Tharp M.D. Mastocytosis. Curr Probl Dermatol 10 September-October (5) (1998) 177-210
2. 2 in patients with systemic mastocytosis. N Engl J Med 303 December (24) (1980) 1400-1404
3. 2 production. Neth J Med 26 1 (1983) 18-20
4. Roberts II L.J. Recurrent syncope due to systemic mastocytosis. Hypertension 6 March-April (2 Pt 1) (1984) 285-294
5. Marone G., Spadaro G., Granata F., and Triggiani M. Treatment of mastocytosis: pharmacologic basis and current concepts. Leuk Res 25 July (7) (2001) 583-594
6. Settipane G.A. Adverse reactions of aspirin and related drugs. Arch Intern Med 141 February (3 Spec No.) (1981) 328-332
7. Abrishami M.A., and Thomas J. Aspirin intolerance: a review. Ann Allergy 39 July (1) (1977) 28-37
8. Roberts II L.J., Fields J.P., and Oates J.A. Mastocytosis without urticaria pigmentosa: a frequently unrecognized cause of recurrent syncope. Trans Assoc Am Physicians 95 (1982) 36-41
9. Worobec A.S. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 14 June (3) (2000) 659-687
10. Roberts II L.J., Turk J.W., and Oates J.A. Shock syndrome associated with mastocytosis: pharmacologic reversal of the acute episode and therapeutic prevention of recurrent attacks. Adv Shock Res 8 (1982) 145-152
11. Butterfield J.H., Kao P.C., Klee G.C., and Yocum M.W. Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization. Mayo Clin Proc 70 May (5) (1995) 481-487
12. Lev E.I., Ramabadran R.S., Guthikonda S., et al. Effect of ranitidine on the antiplatelet effects of aspirin in healthy human subjects. Am J Cardiol 99 January (1) (2007) 124-128 [Epub November 9, 2006]
13. Valent P., Horny H.P., Escribano L., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25 July (7) (2001) 603-625
14. Valent P., Horny H.-P., Li C.Y., et al. Mastocytosis (mast cell disease). In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon, France 291-302
15. Martens-Lobenhoffer J., and Neumann H.J. Determination of 1-methylhistamine and 1-methylimidazoleacetic acid in human urine as a tool for the diagnosis of mastocytosis. J Chromatogr B Biomed Sci Appl 721 January (1) (1999) 135-140
16. Stevenson D.D., and Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 118 October (4) (2006) 773-786 [Epub September 1, 2006]
17. 2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol 111 April (4) (2003) 743-749
18. Wong J.T., Nagy C.S., Krinzman S.J., Maclean J.A., and Bloch K.J. Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. J Allergy Clin Immunol 105 May (5) (2000) 997-1001
19. Peng M.M., and Jick H. A population-based study of the incidence, cause, and severity of anaphylaxis in the United Kingdom. Arch Intern Med 164 February (3) (2004) 317-319
20. Yocum M.W., Butterfield J.H., Klein J.S., Volcheck G.W., Schroeder D.R., and Silverstein M.D. Epidemiology of anaphylaxis in Olmsted County: a population-based study. J Allergy Clin Immunol 104 August (2 Pt 1) (1999) 452-456
21. Metcalfe D.D. The treatment of mastocytosis: an overview. J Invest Dermatol 96 March (3 Suppl.) (1991) 55S-56S
22. Leonards J.R., Levy G., and Niemczura R. Gastrointestinal blood loss during prolonged aspirin administration. N Engl J Med 289 November (19) (1973) 1020-1022
23. Insel P.A. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., and Goodman Gilman A. (Eds). Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. (1996), McGraw-Hill, New York 617-657
24. Lorcerie B., Arveux I., Chauffert B., Dalac S., Lambert D., and Martin F. Aspirin and systemic mastocytosis [letter]. Lancet 334 November (8672) (1989) 1155
25. Wilkin J.K., Wilkin O., Kapp R., Donachie R., Chernosky M.E., and Buckner J. Aspirin blocks nicotinic acid-induced flushing. Clin Pharmacol Ther 31 April (4) (1982) 478-482
26. 2 release following oral administration of niacin in humans. J Invest Dermatol 98 May (5) (1992) 812-815
27. 2) antagonists and cyclooxygenase inhibition. Clin Invest Med 10 January (1) (1987) 1-4
28. Lecomte M., Laneuville O., Ji C., DeWitt D.L., and Smith W.L. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 269 May (18) (1994) 13207-13215
29. van der Donk E.M., Blok W., Kok P.T., and Bruijnzeel P.L. Leukotriene C4 formation by enriched human basophil preparations from normal and asthmatic subjects. Prostaglandins Leukot Essent Fatty Acids 44 September (1) (1991) 11-17
30. 2 generation after activation of rat and human mast cells with anti-IgE. J Immunol 129 October (4) (1982) 1627-1631
31. 2 in man. Prostaglandins 28 December (6) (1984) 755-767
32. 2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 193 January (2) (2001) 255-261
33. 2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 98 September (6) (2001) 1942-1948
34. 2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cell. J Immunol 175 November (10) (2005) 6531-6536
35. 2): a unique biologically active prostaglandin produced enzymatically in vivo in humans. Proc Natl Acad Sci USA 82 September (18) (1985) 6030-6034